GLP-1 Providers That Use 503A Pharmacies: What to Verify

Why You Searched for “503A” Specifically (and What That Tells Us)

Most people searching this exact phrase fall into one of three groups. You probably recognize yourself.

All three groups need the same thing: dated provider disclosures, clear limits on what those disclosures establish, and questions to ask before paying.

What a 503A Pharmacy Actually Is (in Plain English)

A 503A pharmacy is a state-licensed compounding pharmacy that prepares medications for individual patients based on prescriptions. The “503A” comes from Section 503A of the federal Food, Drug, and Cosmetic Act — the law that carved out a legal pathway for traditional pharmacy compounding back in 1997, then strengthened it after the 2012 New England Compounding Center contamination tragedy that killed 64 people. State boards of pharmacy regulate 503A facilities. The FDA can also act on them, but day-to-day oversight is state-level.

For a change to remove a product from the “essentially a copy” definition, the prescriber must determine and document a significant difference for the identified patient. Do not assume that an added vitamin, a small dose change, or a different route automatically satisfies the rule. Other Section 503A conditions and state requirements also apply.

Three things 503A is not:

1. Not FDA-approved. The finished compounded product doesn’t go through FDA review for safety, effectiveness, or quality. Any provider that tells you otherwise is misrepresenting the law.
2. Not a generic. Generics are FDA-approved copies of brand-name drugs whose patents have expired. Compounded semaglutide is not a generic Ozempic. Compounded tirzepatide is not a generic Mounjaro. The FDA has issued dozens of warning letters specifically targeting “same active ingredient” and “generic Wegovy” marketing language.
3. Not the same as 503B. A 503B outsourcing facility is FDA-registered, is subject to current Good Manufacturing Practice (cGMP) requirements, and may compound without patient-specific prescriptions. For compounding from bulk drug substances, Section 503B generally requires the substance to appear on the clinical-need bulks list or the drug to be on FDA’s shortage list. FDA’s current clarification says semaglutide and tirzepatide appear on neither list. Other Section 503B conditions also apply.

The oversight and legal conditions differ. A 503A prescription still has to meet the applicable compounding conditions after a shortage ends. Naming a pharmacy helps you investigate the prescription’s source; it does not establish that the formulation qualifies for the exemptions.

What pharmacy language actually proves (and what it doesn’t)

This table is the lens. Read every provider’s pharmacy page through it.

Is Compounded GLP-1 From a 503A Pharmacy Still Legal in 2026?

Some patient-specific compounding may qualify for Section 503A’s exemptions when all applicable conditions are met. A 503A label or individual prescription alone does not make every compounded semaglutide or tirzepatide product lawful.

Here’s the timeline that matters:

FDA’s April 1, 2026 clarification describes limits on regularly or in inordinate amounts compounding a product that is essentially a copy of an approved drug, and the agency’s current enforcement intent. These statements do not replace the statute or other applicable requirements:

1. A 503A pharmacy generally may not regularly or in inordinate amounts compound a drug that is essentially a copy of a commercially available drug. FDA’s examples and guidance should be read in full; a small dose difference or added ingredient does not automatically qualify a product for an exception.
2. FDA described a limited enforcement intent for certain low-volume compounding of an essentially-copy formulation. This is current enforcement intent, not a statutory carve-out or a guarantee that a particular prescription qualifies.

For a formulation change to establish a significant difference under the copy restriction, the prescriber must determine and document that difference for the identified patient. Do not assume an added vitamin, a small dose change, or a different route automatically satisfies the rule.

• Ask the prescriber to explain the specific patient need and how the prescribed formulation addresses it.
• Ask the pharmacy which product and formulation it will dispense, and verify the state license independently.
• Remember that other federal conditions and state requirements still apply.

A generic “personalized formulation” marketing label does not establish a patient-specific clinical determination. The verification questions below can help you ask for the relevant details, but they cannot determine whether a prescription satisfies the law.

Sources: FDA, “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize” (last updated April 2026); FDA Warning Letters database; Foley & Lardner, “FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products” (April 2026); Wilson Sonsini, “FDA Sends Warning Letters to More Than 50 GLP-1 Compounders” (October 2025); Reuters, March 2026 Novo Nordisk/Hims & Hers settlement coverage.

Which GLP-1 Providers Publicly Name Pharmacy Partners?

More than one provider publishes pharmacy names, but a public network list does not identify which pharmacy will fill an individual prescription. Enhance.MD lists three pharmacy partners in its public terms, alongside other licensed pharmacies. Embody also publishes partner names. MEDVi names pharmacies on its current homepage; its February 2026 FDA warning letter is a separate dated record to consider. Confirm the assigned pharmacy, regulatory role, and current offer directly.

The dates in the final column distinguish October 3, 2026 checks from older provider-row checks. Unchecked rows are not current verification.

The 503A GLP-1 Provider Transparency Matrix — Dated Checks

The Full Provider Breakdown

4. Honest Disclosures: Providers With FDA Warning Letters

FDA has issued warning letters to the three providers below. These dated records deserve review, but a letter alone does not establish present closure status or show that a patient’s medication is contaminated. Ask the provider about corrective action and verify the pharmacy assigned to your prescription.

These are dated regulatory disclosures, not a current safety rating or a determination that an individual product is affected. Confirm the current status with the provider and FDA records before making decisions about treatment.

Sources: FDA Warning Letter to Matthew Stern, CEO MyStart Health LLC (#714755, September 9, 2025); FDA Warning Letter to Direct Meds (September 9, 2025); FDA Warning Letter to MEDVi, LLC dba MEDVi (#721455, February 20, 2026); FDA, “FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s” (March 3, 2026).

5. The “Verify Before Paying” Tier

In the materials sampled on April 29, 2026, these providers did not clearly identify the 503A pathway or assigned pharmacy. That limited review is not a current safety clearance or proof that a provider has no FDA warning letter. Confirm the current pharmacy, license, regulatory role, and offer before paying.

• Yucca Health — strong async, low-friction value path with clear “as low as” pricing and BNPL options like Klarna. Licensed pharmacy language confirmed; explicit 503A status not confirmed in sampled materials. Best fit for value shoppers who’ll send the verification email.
• bmiMD — describes medication as formulated within a licensed State Board of Pharmacy compounding facility, says it works with licensed sterile compounding pharmacies, and discloses that compounded medications are not FDA-approved. Microdose-style positioning. Explicit 503A status not confirmed in sampled materials.
• Willow — flat $299/month positioning, licensed compounding pharmacy language. Explicit 503A status not confirmed. Material context: Willow was named in April 2025 Eli Lilly compounded-tirzepatide litigation; the case was reportedly dismissed in September 2025. Confirm current docket status before relying on this.
• SHED — publishes detailed educational content on 503A vs 503B in its blog, but the specific dispensing pharmacy for an individual prescription wasn’t named in materials we reviewed. Best fit for needle-averse readers if support confirms a 503A partner for your state and formulation.

For all four, the verification approach is the same: send the 7-question script below before checkout. Clean answer? You can proceed. Vague language (“our network of licensed pharmacies”)? You have your answer.

Pharmacies You’ll See Named (and What to Know About Each)

The most common compounding pharmacies that come up in real GLP-1 conversations — Reddit threads, BBB complaint patterns, provider FAQs — are these. Treat this section as a name-recognition primer, not a recommendation list. The pharmacy itself isn’t what you choose; you choose a provider that uses a pharmacy.

• TruMedsRx — Fairfax, Virginia. Named in Enhance.MD’s current terms. Confirm the assigned pharmacy and its current license for your state; this audit did not independently recheck state coverage or patient-volume claims.
• Vios Compounding Pharmacy — Livonia, Michigan. One of Enhance.MD’s three named partners.
• Rite-Away Pharmacy — San Antonio, Texas. One of Enhance.MD’s three named partners.
• Red Rock Compounding Pharmacy / RedRock Pharmacy — Named on Embody and MEDVi public pharmacy lists. Ask for the exact legal entity and dispensing location because naming conventions and listed addresses differ.
• Health Warehouse and Precision Medicine — Named on Embody’s public partner list. Confirm their role in your specific prescription instead of assuming every listed partner compounds every medication.
• Triad Rx — Named by both Embody and MEDVi.
• Beaker Pharmacy & Compounding — Named by MEDVi.
• Strive Pharmacy — Its public “Higher Standards” page describes voluntary PCAB and NABP accreditations, weekly randomized batch testing, a stated ±3% potency variance target, and a stated 99.9%+ sterility/endotoxin pass rate. These are pharmacy claims, not an independent audit. Strive is named as Thrive by Mira’s pharmacy partner. Check the current court docket before relying on older litigation references.
• PerfectRx/PerfectionRx, ProRx, Casa, Pharmacy Hub, SmartPharmaRx — Named as 503A pharmacy partners by OrderlyMeds in its public FAQ.
• Empower Pharmacy — Operates both 503A and 503B operations. Empower’s GLP-1 page describes 503A PCAB-accredited compounding capability. Empower is a direct pharmacy source rather than a consumer-facing telehealth provider; you’re more likely to see it referenced through a clinical platform than to use it directly.
• Hallandale Pharmacy — Frequently mentioned in Reddit GLP-1 threads and in past partnerships with various telehealth platforms. Operates as a 503A. Material concern: Hallandale received an FDA warning letter in 2020 for sterility violations at a previous facility location. Customer review patterns are mixed.
• Belmar Pharma Solutions — Six facilities in Colorado and Florida, four decades of operating history. Named in pharmacy networks used by some platforms.
• Boothwyn Pharmacy — FDA issued a warning letter on January 16, 2026 concerning insanitary conditions and strength, quality, and purity issues in compounded GLP-1 products. Verify current FDA records and ask whether this pharmacy is assigned to your prescription.

If a provider’s support team names a pharmacy you don’t recognize, the verification path is straightforward: search the FDA Warning Letters database, look up the pharmacy on the relevant state board of pharmacy license database, and check the NABP Safe Site Search directory. We walk through the exact steps in the next section.

How to Verify a 503A Pharmacy in Five Minutes (the 7-Question Script)

This is the part you save for later. It’s the most useful single asset on this page, and it works for any GLP-1 provider — not just the ones we ranked. Send this exact script to the provider’s support team before you enter payment information. Save the response. If anything ever goes wrong with your prescription, you’ll have written documentation of what was promised at signup.

Those answers help you verify the source and payment terms. They do not establish product safety, treatment suitability, or compliance with every compounding requirement. Verify the license independently, ask the clinician why a compounded formulation is appropriate for you, and confirm the pharmacy on the dispensed label matches the information provided.

If the answer comes back with vague language like “our network of licensed pharmacies” or “we work with FDA-registered facilities” without specifics, or if the response avoids one or more questions, that is information. You don’t have to draw a hostile conclusion — just acknowledge that you don’t have the disclosure you asked for, and decide whether to proceed without it or switch to a more transparent provider.

The four government and accreditation tools to keep open in browser tabs while you do this:

1. FDA Warning Letters database — fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters. Search the pharmacy name. If a warning letter exists in the past three years, it’ll surface here.
2. State Board of Pharmacy License Lookup — every U.S. state maintains one. Search “[state name] board of pharmacy license lookup.” Confirm the pharmacy holds an active, unrestricted license.
3. NABP Safe Site Search — safe.pharmacy/buy-safely/. The National Association of Boards of Pharmacy maintains a directory of accredited online pharmacies (VIPPS) and a “Not Recommended” list of sites that fail their safety standards.
4. FDA BeSafeRx — fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information. The FDA’s consumer-facing guidance for verifying online pharmacy safety, including the warning signs of an illegal operation.

Keep the provider’s written answers and verify current details again if the pharmacy, medication, state, or offer changes. A checklist helps organize questions; it cannot certify a product, provider, or prescription.

When 503A Compounded Isn’t Right For You: The FDA-Approved Path

A pharmacy disclosure does not determine which treatment is appropriate. Ask a licensed clinician whether an FDA-approved medication can meet your medical needs before considering a compounded product.

Choose an FDA-approved brand-name path if any of these apply:

• You have insurance. Many commercial plans cover branded GLP-1s outright (especially for Type 2 diabetes indications) or cover them after a prior authorization. The cost difference between an insured Wegovy or Zepbound prescription and self-paying $200/month for compounded is usually substantial, and copays vary widely by plan.
• Your medical needs can be met by an FDA-approved drug. FDA recommends reserving compounded drugs for patients whose needs cannot be met by an approved medication. Ask your clinician to explain the reason for the prescribed formulation; a checklist in a comparison article cannot determine whether a prescription satisfies the applicable conditions.
• You want regulatory certainty. Compounded products are not FDA-reviewed. If you don’t want to think about pharmacy partnerships, warning letters, or court rulings, FDA-approved is the path that lets you stop thinking about all of it.
• You’re risk-averse with novel medications. GLP-1s themselves are well-studied at this point, but compounded versions add a second layer of variability (sourcing, sterility, formulation) that the brand product doesn’t carry.

Brand-name options to ask about:

• Wegovy (semaglutide) — FDA-approved for chronic weight management. Available as a pen and a once-daily pill.
• Zepbound (tirzepatide) — FDA-approved for chronic weight management; also has an FDA-approved indication for moderate-to-severe obstructive sleep apnea added in December 2024.
• Foundayo™ (orforglipron) — newer FDA-approved oral GLP-1 for chronic weight management.
• Ozempic (semaglutide) — FDA-approved for Type 2 diabetes; sometimes prescribed off-label for weight loss when clinically appropriate.
• Mounjaro (tirzepatide) — FDA-approved for Type 2 diabetes; may be prescribed off-label when clinically appropriate. Check Ro’s current brand list and availability directly rather than assuming that every FDA-approved product is offered through its program.

Ro Body offers an FDA-approved medication route with insurance support for eligible patients. Membership and medication are billed separately. Compare the current membership offer, medication price, coverage eligibility, and commitment before enrolling.

For the boxed warning and contraindication details on any FDA-approved GLP-1 — including the warnings for personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — refer to the FDA prescribing information for the specific product (Wegovy, Zepbound, Foundayo, Ozempic, Mounjaro). A clinician should review your individual risk profile.

For FDA-approved telehealth options beyond Ro, see our deeper guide to the best brand-name GLP-1 telehealth providers.

Honest Risks of 503A Compounded GLP-1s

Three categories of risk apply to compounded 503A GLP-1s that don’t apply (or apply less) to FDA-approved brand-name medication. Knowing these isn’t a reason to walk away — it’s a reason to choose carefully.

Discuss risks for the specific medication. FDA-approved and compounded GLP-1 drugs may cause adverse effects, but compounded finished products have not undergone FDA’s safety, effectiveness, and quality review. Ask your clinician about the prescribed formulation, contraindications, dosing, and symptoms that require medical attention. Consult the current prescribing information for any FDA-approved product being considered.

Multidose vial storage after first use. FDA’s October 1, 2026 safety page advises consumers to discard a multidose vial of sterile medication within 28 days after first use, even if the compounder’s instructions allow longer. Use a new sterile needle and syringe for each dose. Ask your prescriber and pharmacist how this affects the prescribed supply and packaging. Read FDA’s current advice.

Sources: FDA, “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss” (page updated October 1, 2026; cumulative adverse-event figures through May 31, 2026); Eli Lilly statements about compounded-sample testing and impurity; FDA prescribing information for specific approved products.

What We Actually Verified for This Page

Rechecked October 3, 2026

• Embody’s public 503A FAQ, named pharmacy network, and differing offers across its store, promotional page, and terms.
• Enhance.MD’s terms naming three pharmacy partners and allowing others; Section 503A language on a current product page.
• MEDVi’s named pharmacy network and the February 20, 2026 FDA warning-letter record.
• FDA’s current copy-restriction guidance and court-dependent 503A enforcement-discretion timeline.
• FDA’s October 1, 2026 safety advice, including multidose-vial handling and report counts through May 31, 2026.

Earlier checks

Other provider disclosures, prices, litigation references, and historical enforcement records retain their April 29, 2026 checks unless a row or source says otherwise. They have not all been reverified as of the latest update. Confirm those details before relying on them.

Not independently established

• Which pharmacy will fill a particular patient’s prescription in a particular state.
• Each named pharmacy’s current license, restrictions, quality testing, or current supply.
• Individual clinical records or the legal conditions for a patient’s compounded prescription.
• Closure status for the FDA warning letters discussed here.
• The selected affiliate offer’s checkout charge, renewal price, or commitment.

Public disclosures show what a provider says; they are not independent verification of every pharmacy or product. Cells marked “needs verification” remain unresolved.

Frequently Asked Questions

Which 503A GLP-1 Provider Should You Compare?

Use public disclosures as a starting point, then confirm details for your own prescription and selected offer.

• Enhance.MD publishes three pharmacy names in its terms and also allows other licensed pharmacies. Confirm the pharmacy assigned to you and the selected plan’s terms.
• Embody publishes four pharmacy names and describes 503A compounding in its FAQ. Compare the exact offer’s charge schedule and confirm the pharmacy and formulation before paying.
• Ro Body offers an FDA-approved route to discuss with your clinician. Membership and medication are separate costs; check insurance eligibility and the current offer.
• Use the matching quiz if you need help comparing routes. A quiz recommendation does not replace a licensed clinician’s assessment.

A pharmacy list helps you investigate the source. Use the seven-question script to confirm details, then discuss treatment suitability with your clinician.

Your next-step options:

For pharmacy disclosures · selected-offer details · FDA-approved access.

About This Page

Sources

1. U.S. Food and Drug Administration. "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize." Updated April 2026.
2. U.S. Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss."
3. U.S. Food and Drug Administration. Warning Letter #721455 to MEDVi, LLC dba MEDVi, February 20, 2026.
4. U.S. Food and Drug Administration. Warning Letter #714755 to Matthew Stern, CEO MyStart Health LLC, September 9, 2025.
5. U.S. Food and Drug Administration. Warning Letter to Direct Meds, September 9, 2025.
6. U.S. Food and Drug Administration. "FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s." March 3, 2026.
7. U.S. Food and Drug Administration. "BeSafeRx: Your Source for Online Pharmacy Information."
8. National Association of Boards of Pharmacy. "Find Safe Online Pharmacies." safe.pharmacy
9. Foley & Lardner. "FDA Clarifies Policies for Pharmacy Compounders of GLP-1 Products." April 2026.
10. Spencer Fane. "FDA and Novo Nordisk Warn of GLP-1 Telehealth Compounding Take Down — What's Next?" February 2026.
11. Wilson Sonsini. "FDA Sends Warning Letters to More Than 50 GLP-1 Compounders and Manufacturers." October 2025.
12. Pharmacy Times. "FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown. What's Next?" 2026.
13. Holland & Knight. "Eli Lilly Strikes Back Against Pharmacy Compounders and Telehealth Platforms." June 2025.
14. Buchanan Ingersoll & Rooney PC. "Oral Semaglutide and the GLP-1 Compounding Reckoning." February 2026.
15. Frier Levitt. "The Return of 503B Compounding of GLP-1 Medications." January 2026.
16. Alliance for Pharmacy Compounding. "Compliance alert: 503Bs and GLP-1 compounding." 2025.
17. Strive Pharmacy. "Higher Standards." strivepharmacy.com/higher-standards
18. Ro. "Weight Loss Program Pricing." ro.co/weight-loss/pricing
19. Reuters. "Novo Nordisk and Hims & Hers reach agreement; lawsuit dropped." March 2026.
20. Enhance.MD. Terms of Service (named pharmacy partners).
21. Enhance.MD Terms of Service — named pharmacy partners and other licensed pharmacies; checked October 3, 2026.
22. Enhance.MD Elite product page — public Section 503A statement; checked October 3, 2026.
23. Embody homepage FAQ and pharmacy disclosures — public 503A statement and named partners; checked October 3, 2026.
24. Embody Terms & Conditions — differing offer presentations; checked October 3, 2026.
25. Embody one-month semaglutide supply — offer checked October 3, 2026.
26. Embody one-month tirzepatide supply — offer checked October 3, 2026.
27. Embody promotional page — differing offer presentation; checked October 3, 2026.
28. MEDVi public pharmacy disclosures — named partners; checked October 3, 2026.
29. FDA concerns with unapproved GLP-1 drugs used for weight loss — page updated October 1, 2026; checked October 3, 2026.
30. FDA policies for compounders — copy restriction and court-dependent timelines; checked October 3, 2026.
31. FDA MEDVi Warning Letter #721455 — issued February 20, 2026; record checked October 3, 2026.